Participated · Equity · Apr 2024

Founded in 2001, Elcogen develops proprietary solid oxide fuel cell (SOFC) and solid oxide electrolyser cell (SOEC) technology to enable efficient production of green hydrogen and electricity. Its systems are intended to support heavy‑industry decarbonisation and wider energy‑transition goals. The company manufactures in Estonia and Finland and has served about 160 customers across 30 countries. Elcogen is continuing a development program while expanding manufacturing capacity to meet rising demand. Planned capital will support construction of a new factory in Tallinn with up to 360MW of manufacturing capacity. Strategic partnerships, including collaboration with Baker Hughes and HD Hyundai, are positioned to help commercialise SOEC‑based green hydrogen solutions.

Participated · Seed · Jun 2023

AvoMD builds a clinical AI platform designed to synthesize patient data, surface evidence-based guidance, and support clinicians with end-to-end AI copilots embedded in the EHR. The company positions its product to reduce clinician friction caused by fragmented datasets and multiple applications, aiming to drive measurable improvements in outcomes, cost savings, revenue, and operational efficiency. AvoMD announced a strategic partnership with DynaMed from EBSCO Clinical Decisions to integrate trusted evidence-based knowledge into the EHR via Ask Avo. The business emphasized clinician-centric design, saying it delivers results “with love, not alerts.” Financially, AvoMD has secured a $10M Series A to accelerate product development and commercialization. The announcement credits engaged customers, partners, and its team for supporting the company's growth.

Participated · Series A · Sep 2022

TissenBioFarm develops cultivated whole‑cut meat products by combining animal cells with functional bio‑inks that aim to replicate conventional meat’s texture, marbling, and nutrition. The company says its approach is highly scalable and capable of mass producing whole‑cut cultured meat beyond laboratory scales. It has created three bio‑inks that it claims can be mass‑produced for about $0.33 per 100 grams and that have applications in both cultivated and plant‑based meat. The new funding will support expansion of its research facility and the construction of a production system outside the lab. TissenBioFarm is also working on cell proliferation and differentiation technologies ahead of consumer launches, pending regulatory approvals. Leadership emphasizes reproducing steak‑like thickness, marbling, taste, and competitive pricing as near‑term objectives.